Letrozole (Femara)
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Letrozole, marketed as Femara, is a non-steroidal aromatase inhibitor first approved by the FDA in 1997. Its primary approved use is the treatment of hormone-receptor-positive breast cancer in postmenopausal women, where lowering estrogen helps slow hormone-driven tumor growth.
Outside of oncology, letrozole is discussed in men’s hormone contexts for managing estrogen that rises when testosterone aromatizes — for example on TRT or anabolic-steroid cycles — and for addressing gynecomastia. These applications are off-label and not part of its approved labeling.
It is regarded as one of the most powerful aromatase inhibitors available. That potency is the reason low or every-other-day dosing is commonly reported: the goal in these settings is usually to temper estrogen, not to eliminate it.
How it works
Aromatase is the enzyme that converts androgens into estrogens. Letrozole is a competitive, reversible inhibitor: its triazole structure binds the iron atom in the heme group of the aromatase (cytochrome P-450) enzyme, blocking the final step of estrogen synthesis throughout the body.
Because this blockade is highly selective and near-complete in peripheral tissues, letrozole produces greater estradiol suppression than several other aromatase inhibitors. In published comparisons it has been reported to be substantially more potent than anastrozole at inhibiting intracellular aromatase.
Reported benefits
- Studied and approved for reducing estrogen in hormone-receptor-positive breast cancer
- Reported to control estrogenic effects (such as water retention) attributed to aromatization on androgen protocols
- Reported use in managing gynecomastia, though high-quality evidence specific to letrozole is limited
- Very strong estradiol suppression relative to other aromatase inhibitors
These are reported and studied effects in specific populations, not guaranteed outcomes for any individual.
Considerations & side effects
Letrozole’s strength is also its main risk: it can lower estrogen too far. Excessively suppressed estradiol is commonly associated with joint and bone discomfort, reduced libido, fatigue, and mood changes, and longer-term estrogen deprivation raises concerns for bone mineral density and lipid profiles. In the breast-cancer trials that support its approval, effects on cholesterol and bone health were noted.
Its use for estrogen management or gynecomastia in men is off-label and not well characterized by large controlled trials, so responses vary and monitoring is important. Letrozole is a prescription medication and is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is letrozole?
A potent non-steroidal aromatase inhibitor, sold under the brand name Femara, that lowers estrogen by blocking the enzyme that converts androgens into estradiol.
Is letrozole FDA-approved?
Yes. Letrozole has been FDA-approved since 1997 for treating hormone-receptor-positive breast cancer in postmenopausal women. Its use for estrogen management on TRT or steroid cycles, or for gynecomastia, is off-label.
How does letrozole compare to anastrozole?
Both are non-steroidal aromatase inhibitors, but letrozole is reported to be considerably more potent and to suppress estrogen more completely, which is why lower or less frequent dosing is commonly discussed.
Why is careful dosing emphasized with letrozole?
Because it suppresses estradiol so strongly, it can drive estrogen too low — a state associated with joint discomfort, low libido, and mood changes. This is why very conservative, spread-out dosing is commonly reported.
References
Related compounds
Aromatase inhibitor (AI). Used to control estrogen levels during TRT. Brand name Arimidex.
A steroidal, irreversible ('suicide') aromatase inhibitor that lowers estradiol by permanently binding the aromatase enzyme. Used on TRT or cycles to manage high estrogen; unlike anastrozole it does not cause a rebound.
A SERM that blocks estrogen at breast tissue, used by men to prevent or treat gynecomastia and as a post-cycle therapy agent to restore the HPG axis. Unlike aromatase inhibitors it does not lower systemic estradiol.